Biodesy, a Burlingame, Calif.-based provider of real-time protein function analysis for research and clinical applications, secured $15m in Series A financing.
Backers included 5AM Ventures, Pfizer Venture Investments and Roche Venture Fund.
The company intends to use the funds to further develop its technology.
founded by Chief Scientific Officer Joshua Salafsky, Ph.D. and led by newly appointed CEO Greg Yap, Biodesy develops novel systems to analyze real-time protein function for research and clinical applications including drug discovery, structural biology, and clinical biomarkers.
Its technology, based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time. Since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how our bodies function and respond to treatments.